이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

신세포암(RCC) 환자를 대상으로 한 벨주티판(MK-6482) 및 잔잘린티닙의 임상 연구 (LITESPARK-034/LS-034/MK-6482-034)

2026년 11월 12일 업데이트: Merck Sharp & Dohme LLC

PD-1/L1 및 VEGF-TKI 치료를 순차적으로 또는 병합하여 투여한 후 진행된 진행성 RCC 환자를 대상으로 벨주티판 + 잔잘린티닙 대 벨주티판 + 위약의 3상 무작위 이중맹검 연구 (LITESPARK-034)

Researchers are looking for new ways to treat advanced renal cell carcinoma (RCC).

A standard (usual) treatment for certain people with RCC is belzutifan (a study medicine), which is a targeted therapy. Targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread. Researchers want to learn if adding another targeted therapy called zanzalintinib (another study medicine) can treat more people with advanced RCC than belzutifan alone.

The goal of this study is to learn if people who receive belzutifan and zanzalintinib live longer overall and without the cancer getting worse compared to people who receive belzutifan and placebo.

연구 개요

상태

모병

정황

개입 / 치료

연구 유형

중재적

등록 (추정된)

758

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Attica
      • Athens, Attica, 그리스, 185 47
        • 모병
        • Metropolitan Hospital ( Site 1402)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +302104809667
      • Athens, Attica, 그리스, 124 62
        • 모병
        • ATTIKON GENERAL UNIVERSITY HOSPITAL ( Site 1401)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +302105832549
      • Athens, Attica, 그리스, 115 28
        • 모병
        • Alexandra General Hospital of Athens ( Site 1400)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +302132162543
    • Limburg
      • Maastricht, Limburg, 네덜란드, 6229 HX
        • 모병
        • Maastricht UMC+ ( Site 1901)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +31433877025
    • North Holland
      • Amsterdam, North Holland, 네덜란드, 1066 CX
        • 모병
        • Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL) ( Site 1900)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +3120 512 9111
    • South Holland
      • Schiedam, South Holland, 네덜란드, 3118 JH
        • 모병
        • Franciscus Gasthuis & Vlietland, Locatie Vlietland ( Site 1903)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +31108931441
      • The Hague, South Holland, 네덜란드, 2545 AA
        • 모병
        • Haga Ziekenhuis locatie Leyweg ( Site 1906)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +3170 210 2143
      • Seoul, 대한민국, 05505
        • 모병
        • Asan Medical Center ( Site 2901)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +82-2-3010-5977
      • Seoul, 대한민국, 06351
        • 모병
        • Samsung Medical Center ( Site 2902)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +82-2-3410-1767
      • Seoul, 대한민국, 03722
        • 모병
        • Severance Hospital, Yonsei University Health System ( Site 2903)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +82-2-2228-8138
    • Capital Region
      • Herlev, Capital Region, 덴마크, 2730
        • 모병
        • Herlev Hospital ( Site 1002)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 00 45 38689191
    • Central Jutland
      • Aarhus, Central Jutland, 덴마크, 8200
        • 모병
        • Aarhus Universitetshospital, Skejby ( Site 1001)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +4591167472
    • Region Syddanmark
      • Odense, Region Syddanmark, 덴마크, 5000
        • 모병
        • Odense Universitets Hospital ( Site 1000)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +4566113333
      • Berlin, 독일, 10117
        • 모병
        • Charité Universitaetsmedizin Berlin - Campus Mitte ( Site 1312)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +4930450515288
    • Bavaria
      • Augsburg, Bavaria, 독일, 86156
        • 모병
        • Universitaetsklinikum Augsburg ( Site 1316)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +498214002348
      • Munich, Bavaria, 독일, 81675
        • 모병
        • klinikum rechts der isar der technischen universität münchen ( Site 1315)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 00498941402522
    • Thuringia
      • Jena, Thuringia, 독일, 07747
        • 모병
        • Universitätsklinikum Jena ( Site 1313)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +4936419329970
    • California
      • Duarte, California, 미국, 91010
        • 모병
        • City of Hope Comprehensive Cancer Center ( Site 0129)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 877-817-9982
      • Irvine, California, 미국, 92618
        • 모병
        • City of Hope Lennar Foundation Cancer Center ( Site 0142)
        • 연락하다:
          • Study Coordinator
          • 전화번호: see site 0129
    • Georgia
      • Marietta, Georgia, 미국, 30060
        • 모병
        • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0102)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 770-281-5124
    • Kentucky
      • Louisville, Kentucky, 미국, 40202
        • 모병
        • University of Louisville, James Graham Brown Cancer Center ( Site 0133)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 502-562-4673
      • Louisville, Kentucky, 미국, 40207
        • 모병
        • Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0104)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 502-899-3366
    • Massachusetts
      • Boston, Massachusetts, 미국, 02215
        • 모병
        • Beth Israel Deaconess Medical Center ( Site 0139)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 617-667-7000
      • Boston, Massachusetts, 미국, 02215
        • 모병
        • Dana Farber Cancer Institute ( Site 0135)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 617-632-3000
    • Michigan
      • Grand Rapids, Michigan, 미국, 49503
        • 모병
        • The Cancer and Hematology Centers ( Site 0123)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 616-954-9800
    • Missouri
      • St Louis, Missouri, 미국, 63110
        • 모병
        • Washington University School of Medicine ( Site 0114)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 314-362-7355
    • New Jersey
      • Hackensack, New Jersey, 미국, 07601
        • 모병
        • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0108)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 551-996-5900
      • Morristown, New Jersey, 미국, 07960
        • 모병
        • Atlantic Health System Morristown Medical Center ( Site 0109)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 973-971-7960
    • New York
      • New York, New York, 미국, 10065
        • 모병
        • Memorial Sloan Kettering Cancer Center ( Site 0126)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 347-798-9213
    • Tennessee
      • Germantown, Tennessee, 미국, 38138
        • 모병
        • The West Clinic, P.C. ( Site 0115)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 901-683-0055
    • Texas
      • Dallas, Texas, 미국, 75390
        • 모병
        • UT Southwestern Medical Center ( Site 0119)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 214-648-3111
    • Espírito Santo
      • Vitória, Espírito Santo, 브라질, 29055-450
        • 모병
        • CEDOES ( Site 0303)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +552721250202
    • Paraná
      • Curitiba, Paraná, 브라질, 80510-130
        • 모병
        • Instituto do Câncer e Transplante de Curitiba ( Site 0300)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +55 41 99205-7755
    • Rio Grande do Norte
      • Natal, Rio Grande do Norte, 브라질, 59062-000
        • 모병
        • Liga Norte Riograndense Contra o Câncer ( Site 0307)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +55 84 4009-5595
    • São Paulo
      • Ribeirão Preto, São Paulo, 브라질, 14026-610
        • 모병
        • Hope - Humanizacao Em Oncologia, Pesquisa E Ensino ( Site 0306)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +55 16 3913-8181
      • São José do Rio Preto, São Paulo, 브라질, 15090-000
        • 모병
        • Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0302)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +55 17 3201-5054
      • Barcelona, 스페인, 08035
        • 모병
        • Hospital Universitari Vall d Hebron ( Site 2303)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +34934894350
      • Las Palmas, 스페인, 35016
        • 모병
        • Hospital Insular de Gran Canaria ( Site 2308)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +34928441738
      • Madrid, 스페인, 28041
        • 모병
        • Hospital Universitario 12 de Octubre ( Site 2300)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +34913908339
      • Valencia, 스페인, 46009
        • 모병
        • Fundación Instituto Valenciano de Oncología ( Site 2307)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +34961114229
    • Andalusia
      • Seville, Andalusia, 스페인, 41013
        • 모병
        • Hospital Universitario Virgen del Rocio ( Site 2306)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +34955013068
    • Barcelona
      • L'Hospitalet de Llobregat, Barcelona, 스페인, 08908
        • 모병
        • Institut Català d'Oncologia - L'Hospitalet ( Site 2305)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +34932607744
    • Madrid, Comunidad de
      • Madrid, Madrid, Comunidad de, 스페인, 28007
        • 모병
        • HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON ( Site 2301)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +34914269393
      • CABA, 아르헨티나, C1426ANZ
        • 모병
        • Instituto Alexander Fleming ( Site 0252)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +541132218900
      • La Rioja, 아르헨티나, X5004BAL
        • 모병
        • Centro Oncológico Riojano Integral ( Site 0256)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +543804436443X108
      • San Juan, 아르헨티나, J5402BGA
        • 모병
        • COE (Centro Oncológico de Excelencia) ( Site 0259)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +54 2644229585
    • Buenos Aires
      • CABA, Buenos Aires, 아르헨티나, C1426AHB
        • 모병
        • Centro Oncologico Korben ( Site 0254)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +541159507952
      • Ciudad de Buenos Aires, Buenos Aires, 아르헨티나, 1181
        • 모병
        • Hospital Italiano de Buenos Aires ( Site 0253)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +541149590200
      • Mar del Plata, Buenos Aires, 아르헨티나, B7600FZO
        • 모병
        • Instituto de Investigaciones Clinicas Mar del Plata ( Site 0250)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +542234963224
    • Córdoba Province
      • Río Cuarto, Córdoba Province, 아르헨티나, X5800ALB
        • 모병
        • Centro Privado de RMI Río Cuarto S.A. II ( Site 0255)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +543584620273
    • Santa Fe Province
      • Rosario, Santa Fe Province, 아르헨티나, S2000DSV
        • 모병
        • Sanatorio Parque ( Site 0251)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +5493416955611
      • Rosario, Santa Fe Province, 아르헨티나, S2000KZE
        • 모병
        • Instituto de Oncología de Rosario ( Site 0257)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +543414484830
      • Birmingham, 영국, B15 2GW
        • 모병
        • University Hospitals Birmingham NHS Foundation Trust ( Site 2610)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +4407789651543
      • Cardiff, 영국, CF14 2TL
        • 모병
        • Velindre Cancer Centre ( Site 2612)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +442920615888
      • Southampton, 영국, SO16 6YD
        • 모병
        • University Hospital of Southampton ( Site 2606)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 023 8077 7222
    • Cambridgeshire
      • Cambridge, Cambridgeshire, 영국, CB2 0QQ
        • 모병
        • Addenbrookes Hospital ( Site 2605)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +441223805000
    • Edinburgh, City of
      • Edinburgh, Edinburgh, City of, 영국, EH4 2XU
        • 모병
        • Western General Hospital ( Site 2608)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +441315371398
    • Glasgow City
      • Glasgow, Glasgow City, 영국, G12 0YN
        • 모병
        • The Beatson West of Scotland Cancer Centre ( Site 2602)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +441413019916
    • Leicestershire
      • Leicester, Leicestershire, 영국, LE1 5WW
        • 모병
        • Leicester Royal Infirmary ( Site 2604)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 0300 303 1573
    • London, City of
      • Northwood, London, City of, 영국, HA6 2RN
        • 모병
        • Mount Vernon Hospital ( Site 2607)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +4401923826111
    • Manchester
      • Withington, Manchester, 영국, M20 4BX
        • 모병
        • The Christie Hospital NHS Foundation Trust ( Site 2601)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 0161 918 2546
      • Haifa, 이스라엘, 3109601
        • 모병
        • Rambam Health Care Campus ( Site 1600)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +97247772688
      • Kfar Saba, 이스라엘, 4428164
        • 모병
        • Meir Medical Center. ( Site 1603)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +97297472555
      • Petah Tikva, 이스라엘, 4941492
        • 모병
        • Rabin Medical Center ( Site 1602)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 97239378074
      • Ramat Gan, 이스라엘, 5265601
        • 모병
        • Sheba Medical Center ( Site 1601)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 97235303030
      • Bari, 이탈리아, 70124
        • 모병
        • Azienda Ospedaliera Policlinico di Bari ( Site 1802)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 00390805593767
      • Bologna, 이탈리아, 40138
        • 모병
        • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 1803)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +390512142204
      • Milan, 이탈리아, 20133
        • 모병
        • Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1800)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 02 2390 3028
      • Perugia, 이탈리아, 06132
        • 모병
        • AO Santa Maria della Misericordia ( Site 1805)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +39 0755784188
      • Roma, 이탈리아, 00168
        • 모병
        • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 1801)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 00390630155202
      • Roma, 이탈리아, 00144
        • 모병
        • Istituto Nazionale Tumori Regina Elena ( Site 1804)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +39 0652666919
    • Emilia-Romagna
      • Meldola, Emilia-Romagna, 이탈리아, 47014
        • 모병
        • IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" ( Site 1809)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +390543739100
    • Milano
      • Rozzano, Milano, 이탈리아, 20089
        • 모병
        • Istituto Clinico Humanitas ( Site 1808)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 0282244061
    • Treviso
      • Castelfranco Veneto, Treviso, 이탈리아, 31033
        • 모병
        • Istituto Oncologico Veneto IRCCS ( Site 1806)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +39 0423732336
    • Tuscany
      • Florence, Tuscany, 이탈리아, 50134
        • 모병
        • Azienda Ospedaliera Universitaria Careggi ( Site 1807)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +390557949648
      • Hradec Králové, 체코, 500 05
        • 모병
        • Fakultni nemocnice Hradec Kralove ( Site 0902)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +420727854666
      • Olomouc, 체코, 779 00
        • 모병
        • Fakultni nemocnice Olomouc ( Site 0901)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +420588445923
      • Prague, 체코, 150 06
        • 모병
        • Fakultni nemocnice v Motole ( Site 0900)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +420734236410
      • Prague, 체코, 128 08
        • 모병
        • Fakulti poliklinika ( Site 0906)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +420224966405
    • Brno-mesto
      • Brno, Brno-mesto, 체코, 656 53
        • 모병
        • Masarykuv onkologicky ustav ( Site 0903)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +420543132216
    • Ostrava Mesto
      • Ostrava, Ostrava Mesto, 체코, 708 52
        • 모병
        • Fakultni nemocnice Ostrava ( Site 0904)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +420597374322
    • Coquimbo Region
      • La Serena, Coquimbo Region, 칠레, 1720430
        • 모병
        • IC La Serena Research ( Site 0405)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 56958646664
    • Los Lagos Region
      • Port Montt, Los Lagos Region, 칠레, 5500243
        • 모병
        • Clínica Puerto Montt ( Site 0404)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +56985383586
    • Region M. de Santiago
      • Santiago, Region M. de Santiago, 칠레, 7500921
        • 모병
        • Fundacion Arturo Lopez Perez ( Site 0401)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 56224205098
      • Santiago, Region M. de Santiago, 칠레, 8420383
        • 모병
        • Bradfordhill ( Site 0400)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 56229490970
    • Valparaiso
      • Viña del Mar, Valparaiso, 칠레, 2520598
        • 모병
        • ONCOCENTRO APYS ( Site 0403)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 56323320850
    • Ontario
      • Ottawa, Ontario, 캐나다, K1H 8L6
        • 모병
        • The Ottawa Hospital Cancer Centre ( Site 0003)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 613-737-7700
    • Quebec
      • Québec, Quebec, 캐나다, G1J 1Z4
        • 모병
        • Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0001)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 418-525-4444
      • Adana, 터키 (Türkiye), 01140
        • 모병
        • Adana Medical Park Seyhan Hastanesi ( Site 2505)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +905372688986
      • Ankara, 터키 (Türkiye), 06620
        • 모병
        • Ankara University Health Practice and Research Hospitals ( Site 2506)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +90 312 595 71 12
      • Edirne, 터키 (Türkiye), 22030
        • 모병
        • Trakya University Medical Faculty Hospital ( Site 2502)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +9005378528123
      • Istanbul, 터키 (Türkiye), 34010
        • 모병
        • Koc Universitesi Hastanesi ( Site 2501)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 0090 850 250 8 250
      • Izmir, 터키 (Türkiye), 35080
        • 모병
        • Ege Universitesi Hastanesi ( Site 2503)
        • 연락하다:
          • Study Coordinator
          • 전화번호: 0 232 343 43 43
    • Ankara
      • Sıhhiye, Ankara, 터키 (Türkiye), 06230
        • 모병
        • Hacettepe Universite Hastaneleri ( Site 2500)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +905439340493
    • Greater Poland Voivodeship
      • Skórzewo, Greater Poland Voivodeship, 폴란드, 60-185
        • 모병
        • AIDPORT Sp. z o.o. ( Site 2118)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +48570783100
    • Lesser Poland Voivodeship
      • Krakow, Lesser Poland Voivodeship, 폴란드, 30-727
        • 모병
        • Pratia MCM Krakow ( Site 2115)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +48122958160
    • Masovian Voivodeship
      • Siedlce, Masovian Voivodeship, 폴란드, 08-110
        • 모병
        • Mazowiecki Szpital Wojewódzki im. Sw. Jana Pawla II w Siedlcach Sp. z o.o. ( Site 2102)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +48256403300
      • Warsaw, Masovian Voivodeship, 폴란드, 02-172
        • 모병
        • MTZ Clinical Research Powered by Pratia ( Site 2107)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +48225725959
      • Warsaw, Masovian Voivodeship, 폴란드, 02-781
        • 모병
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Moczowego ( Site 2100)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +48225462331
    • Silesian Voivodeship
      • Gliwice, Silesian Voivodeship, 폴란드, 44-102
        • 모병
        • Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 2106)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +48322788237
    • Alpes-Maritimes
      • Nice, Alpes-Maritimes, 프랑스, 06189
        • 모병
        • Centre Antoine Lacassagne ( Site 1209)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +33492031538
    • Bouches-du-Rhone
      • Marseille, Bouches-du-Rhone, 프랑스, 13003
        • 모병
        • Hopital Europeen Marseille ( Site 1216)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +33413427427
    • Haute-Garonne
      • Toulouse, Haute-Garonne, 프랑스, 31059
        • 모병
        • LBM ONCOPOLE CLAUDIUS REGAUD ( Site 1215)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +33531155050
    • Maine-et-Loire
      • Angers, Maine-et-Loire, 프랑스, 49933
        • 모병
        • CHU Angers ( Site 1204)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +33241354694
    • Pays de la Loire Region
      • Le Mans, Pays de la Loire Region, 프랑스, 72000
        • 모병
        • Clinique Victor Hugo Le Mans-Oncology-Radiotherapy ( Site 1203)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +33 243297908
      • Saint Priest En Jarez, Pays de la Loire Region, 프랑스, 42271
        • 모병
        • CHU de Saint-Etienne ( Site 1202)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +33477917082
    • Val-de-Marne
      • Villejuif, Val-de-Marne, 프랑스, 94800
        • 모병
        • Gustave Roussy ( Site 1214)
        • 연락하다:
          • Study Coordinator
          • 전화번호: +33142114211
    • New South Wales
      • Macquarie University, New South Wales, 호주, 2109
        • 정지된
        • Macquarie University ( Site 2700)
    • Queensland
      • Woolloongabba, Queensland, 호주, 4102
        • 정지된
        • Princess Alexandra Hospital ( Site 2703)
    • Victoria
      • Melbourne, Victoria, 호주, 3000
        • 정지된
        • Peter MacCallum Cancer Centre ( Site 2702)
    • Western Australia
      • Murdoch, Western Australia, 호주, 6150
        • 정지된
        • Fiona Stanley Hospital ( Site 2704)

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

  • Has a histologically confirmed diagnosis of unresectable, advanced renal cell carcinoma (RCC) with clear cell component (with or without sarcomatoid features) ie, Stage IV RCC per American Joint Committee on Cancer (8th Edition)
  • Has measurable disease per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1)
  • Has received no more than 3 prior systemic regimens for RCC, including only 1 prior anti-Programmed Cell Death-1/Programmed Cell Death 1 Ligand 1 therapy

Exclusion Criteria:

For exclusion criteria: The main exclusion criteria include but are not limited to the following:

  • Has any of the following: a pulse oximeter reading <92% at rest, requires intermittent supplemental oxygen, or required chronic supplemental oxygen
  • Has clinically significant cardiovascular disease within 12 months from first dose of study intervention
  • Has deep vein thrombosis within 3 months before randomization unless stable, asymptomatic, and treated with therapeutic anticoagulation for at least 4 weeks before randomization
  • Has a left ventricular ejection fraction ≤50% or below the institutional (or local laboratory) normal range as determined by multigated acquisition or echocardiogram
  • Has had major surgery within 8 weeks before randomization
  • Has current pneumonitis/interstitial lung disease
  • Has a history of human immunodeficiency virus infection
  • Has Hepatitis B or Hepatitis C virus infection
  • Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
  • Has a history of solid organ transplant
  • Has not adequately recovered from major surgery or has ongoing surgical complications

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 삼루타

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Belzutifan + Zanzalintinib

Participants will receive 120 mg belzutifan orally and 60 mg zanzalintinib once daily for approximately 24 months.

Tablet for oral administration.

다른 이름들:
  • MK-6482
  • PT2977
  • 웰리레그

Tablet for oral administration.

다른 이름들:
  • XL092
활성 비교기: Belzutifan + Placebo

Participants will receive 120 mg belzutifan orally and zanzalintinib-matching placebo once daily for approximately 24 months.

Tablet for oral administration.

다른 이름들:
  • MK-6482
  • PT2977
  • 웰리레그

Zanzalintinib-matching placebo tablet for oral administration.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Progression-free Survival (PFS)
기간: Up to approximately 30 months

PFS is defined as the time from randomization to the first documented disease progression per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) based on blinded independent central review (BICR) or death due to any cause, whichever occurs first.

Up to approximately 30 months
Overall Survival (OS)
기간: Up to approximately 50 months

OS is defined as the time from randomization to death due to any cause.

Up to approximately 50 months

2차 결과 측정

결과 측정
측정값 설명
기간
Objective Response Rate (ORR)
기간: Up to approximately 30 months

ORR is defined as the percentage of participants who have achieved confirmed Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by BICR.

Up to approximately 30 months
Duration of Response (DOR)
기간: Up to approximately 30 months

DOR is defined as the interval from the first documented evidence of a CR (disappearance of all target lesions) or a PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 until Progressive Disease (PD) or death due to any cause, whichever occurs first, in participants demonstrating a best confirmed response of CR or PR. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD.

Up to approximately 30 months
Number of Participants Who Experience One or More Adverse Events (AEs)
기간: Up to approximately 25 months

An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who experience an AE will be reported.

Up to approximately 25 months
Number of Participants who Discontinue Study Treatment Due to an AE
기간: Up to approximately 24 months

An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who discontinue study treatment due to an AE will be reported.

Up to approximately 24 months
Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score
기간: Baseline and up to approximately 25 months

EORTC QLQ-C30 is a questionnaire to assess the overall quality of life (QoL) of cancer patients. Participant responses to questions regarding Global Health Status (GHS; "How would you rate your overall health during the past week?") and QoL ("How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) is computed by averaging the raw scores of the 2 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The change from baseline in GHS and QoL combined score will be presented.

Baseline and up to approximately 25 months
Change from Baseline in the EORTC QLQ-C30 Physical Functioning (Items 1-5) Combined Score
기간: Baseline and up to approximately 25 months

EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 was computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The change from baseline in EORTC QLQ-C30 physical functioning (Items 1-5) combined score will be presented.

Baseline and up to approximately 25 months
Change from Baseline in the EORTC QLQ-C30 Role Functioning (Items 6 and 7) Combined Score
기간: Baseline and up to approximately 25 months

The EORTC QLQ-C30 is a cancer specific health-related quality of life questionnaire. The role functioning score is based on participant responses to questions scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score was computed by averaging the raw scores of Items 6 and 7 and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. Higher scores indicate better role functioning. The change from baseline in EORTC QLQ-C30 Role Functioning (Items 6 and 7) combined score will be reported.

Baseline and up to approximately 25 months
Change From Baseline in Disease Symptoms Using the Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-related Symptoms (FKSI-DRS) (Items 1-9) Score
기간: Baseline and up to approximately 25 months

The FKSI-DRS index consists of a 9-item questionnaire that assesses the extent of participant symptoms from kidney cancer. Each item is scored on a 5-point scale (0=not at all to 4=very much). FKSI-DRS total score ranged from 0 (most severe symptoms) to 36 (no symptoms) with a higher score indicating a better outcome.

Baseline and up to approximately 25 months
Time to Deterioration (TTD) in EORTC QLQ-C30 Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score
기간: Up to approximately 25 months

EORTC QLQ-C30 is a questionnaire to assess QoL of cancer patients. Participant responses to questions on GHS ("How would you rate your overall health during the past week?") and QoL ("How would you rate your overall QoL during the past week?") were scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) was computed by averaging raw scores of the 2 items and applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in GHS-QoL combined score. A longer TTD indicates a better outcome.

Up to approximately 25 months
TTD in EORTC QLQ-C30 Physical Functioning (Items 1-5) Score
기간: Up to approximately 25 months

EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 was computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in physical functioning (Items 1 to 5). A longer TTD indicates a better outcome.

Up to approximately 25 months
TTD in EORTC QLQ-C30 Role Functioning (Items 6 and 7) Score
기간: Up to approximately 25 months

EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to questions about their role functioning (Items 6 and 7) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of Items 6 and 7 was computed by averaging the raw scores of the items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in role functioning (Items 6 and 7). A longer TTD indicates a better outcome.

Up to approximately 25 months
TTD in Disease Symptoms Using the FKSI-DRS (Items 1-9) Score
기간: Up to approximately 25 months

TTD is defined as time from the first dose of study treatment to the date of deterioration of FKSI-DRS score. The FKSI-DRS index consists of a 9-item questionnaire that assesses the extent of participant symptoms from kidney cancer. Each item is scored on a 5-point scale (0=not at all to 4=very much). FKSI-DRS total score ranged from 0 (most severe symptoms) to 36 (no symptoms) with a higher score indicating a better outcome. Deterioration is defined as a 3-point decrease (i.e. lower score) in symptom score and the time to true deterioration is the time to first onset of 3 or more decreases from baseline with confirmation under right-censoring rule (the last observation). A longer TTD indicates a better outcome.

Up to approximately 25 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 연구 책임자: Medical Director, Merck Sharp & Dohme LLC

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 4월 9일

기본 완료 (추정된)

2030년 11월 27일

연구 완료 (추정된)

2030년 11월 27일

연구 등록 날짜

최초 제출

2026년 3월 20일

QC 기준을 충족하는 최초 제출

2026년 3월 20일

처음 게시됨 (실제)

2026년 3월 24일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 13일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 12일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 6482-034
  • U1111-1311-4692 (레지스트리 식별자: UTN)
  • 2024-516993-31-00 (레지스트리 식별자: EU CT)
  • LITESPARK-034 (기타 식별자: MSD)
  • MK-6482-034 (기타 식별자: MSD)
  • LS-034 (기타 식별자: MSD)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .